Pulse nav.journalClub 活発な議論トレンド探索研究者

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

プライバシーポリシー

ホーム探索 nav.journalClub トレンド

⌘+K

Advancing Access to Cell and Gene Therapies in Medicaid | Synapse

May 22, 2024

メディケイドにおける細胞および遺伝子治療へのアクセスの向上

Key Points

Key points are not available for this paper at this time.

Abstract

この見解は、メディケアとメディケイド革新センター、州メディケイド機関、患者、および製造業者の間での支払いモデルの要素と実施上の課題を示しています。

Like

Bookmark

Share

Like

Bookmark

Share

Cite This Study

Kannarkat et al. (水曜日) はこの問題を研究しました。

synapsesocial.com/papers/68e68e7db6db643587615dab https://doi.org/https://doi.org/10.1001/jama.2024.6224

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts2019 · 9 citations
2<p>Development of a Severity Classification System for Sickle Cell Disease</p>2020 · 45 citations
3Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe2017 · 134 citations
4A network model to predict the risk of death in sickle cell disease2007 · 159 citations
5Somatic Symptom Burden in Adults with Sickle Cell Disease Predicts Pain, Depression, Anxiety, Health Care Utilization, and Quality of Life: The PiSCES Project2011 · 92 citations